Satellos Bioscience announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (“Duchenne” or “DMD”).
The study will evaluate SAT-3247 in 51 ambulatory children with DMD aged 7, 8 or 9 years of age. Primary endpoints include safety, tolerability and effect on muscle force. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration. Learn More: Potential of SAT-3247 to Restore Muscle Regeneration in Duchenne Published in Nature
“Designed as a potential pivotal trial, BASECAMP marks a significant step for Satellos in evaluating the therapeutic potential of SAT-3247 in children living with Duchenne,” said Satellos Co-founder and CEO Frank Gleeson. “Data generated from BASECAMP could play a meaningful role in accelerating the development of SAT-3247 as a novel treatment for this disease.”
In which countries will the SAT-3247 clinical trials begin?
The BASECAMP trial is actively enrolling, and Satellos plans to establish 25 sites for the study at clinical centers in the United States, Europe, the United Kingdom, Australia, Canada and Serbia. Read More: How Does My Child Participate in Clinical Trials for Duchenne?
“BASECAMP will focus on an important period in Duchenne when muscle health and function begin to decline more rapidly,” said Satellos Chief Medical Officer Wildon Farwell, M.D. “Treatment options remain limited for this devastating disease, and this study will evaluate a novel approach to potentially increase muscle regeneration and thereby improve function among children with Duchenne.”
What is SAT-3247?
SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne and other degenerative or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD, independent of dystrophin and regardless of exon mutation status.
Follow This Page >>> All Clinical Trials for Duchenne
